Atrial fibrillation (AF) affects more than 3 million Americans and is expected to reach
epidemic proportions as the US population ages. The presence of AF increases lifetime …

Atrial fibrillation (AF) is the most common clinically significant cardiac arrhythmia in the
United States and increases the risk of stroke 4.5-fold. Stroke can result in substantial …

Dabigatran etexilate is the first commercially available oral direct thrombin inhibitor. A single
trial has studied patients at risk for stroke associated with nonvalvular atrial fibrillation; in this …

There is a renewed interest in antithrombotic therapy for stroke prevention in patients with
atrial fibrillation, with the first comprehensive clinical trial demonstrating opposition to …

BACKGROUND: Until recently, warfarin was the only oral anticoagulant available in the
United States. Its narrow therapeutic index, interpatient variability in dose response, and …

Atrial fibrillation (AF) is well known as one of the leading causes of stroke and systemic
embolism. Anticoagulation therapy is recommended in all patients at moderate-to-high risk …

Dabigatran etexilate is an oral prodrug of dabigatran, a direct thrombin inhibitor, that
provides the first available oral anticoagulant alternative to warfarin for reducing the risk of …

Dabigatran was the first direct-acting oral anticoagulant approved by the US Food and Drug
Administration for prevention of stroke and systemic embolism in people with atrial …

For more than 5 decades, warfarin has been the mainstay of therapy when oral
anticoagulation is required. It has been shown to be effective in the prevention as well as …

A number of novel anticoagulants are moving through various stages of drug development.
Recently, the United States Food and Drug Administration approved the oral direct thrombin …